US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

BioRestorative Therapies Inc

us-stock
To Invest in {{usstockname}}
us-stock
$1.08 0.0385(3.85%) BRTX at 04 Dec 2025 04:27 PM Biotechnology
Lowest Today 1.0661
Highest Today 1.07
Today’s Open 1.0661
Prev. Close 1.04
52 Week High 2.55
52 Week Low 0.98
Day’s Range: Low 1.0661 High 1.07
52-Week Range: Low 0.98 High 2.55
1 day return -
1 Week return -2.75
1 month return -28.13
3 month return -32.48
6 month return -41.11
1 year return -27.89
3 year return -69.54
5 year return -
10 year return -

Institutional Holdings

Geode Capital Management, LLC 0.68

Wealth Alliance, LLC 0.50

StoneX Group Inc 0.47

Morgan Stanley - Brokerage Accounts 0.44

Vanguard Group Inc 0.37

Fidelity Extended Market Index 0.34

State Street Corp 0.26

Vanguard Institutional Extnd Mkt Idx Tr 0.26

US FINANCIAL ADVISORS, LLC 0.21

Fidelity Total Market Index 0.17

Virtu Financial LLC 0.15

Newman Dignan & Sheerar Inc 0.14

Fidelity Series Total Market Index 0.11

Fidelity Nasdaq Composite Index 0.05

Northern Trust Extended Eq Market Idx 0.03

NT Ext Equity Mkt Idx Fd - L 0.03

Advisor Group Holdings, Inc. 0.03

Spartan Total Market Index Pool G 0.02

Tower Research Capital LLC 0.02

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.01

NT Ext Eq Mkt Indx Fd DC Lend T3 0.01

Spartan Extended Market Index Pool F 0.00

SBI Securities Co Ltd 0.00

Bank of America Corp 0.00

Citadel Advisors Llc 0.00

TD Waterhouse Canada Inc 0.00

UBS Group AG 0.00

Market Status

Strong Buy: 1

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 9.05 M

PB Ratio 4.3187

PE Ratio 0.0

Enterprise Value -3.56 M

Total Assets 12.28 M

Volume 17454

Company Financials

Annual Revenue FY24:145800 0.1M, FY23:130200 0.1M, FY22:119800 0.1M, FY21:46000 0.0M, FY20:130000 0.1M

Annual Profit FY24:145800 0.1M, FY23:null 0.0M, FY22:119800 0.1M, FY21:46000 0.0M, FY20:130000 0.1M

Annual Net worth FY24:-10417704 -10.4M, FY23:-15937819 -15.9M, FY22:-18015513 -18.0M, FY21:-29938605 -29.9M, FY20:-17921113 -17.9M

Quarterly Revenue Q3/2025:11800 0.0M, Q2/2025:303300 0.3M, Q1/2025:25000 0.0M, Q3/2024:233600 0.2M, Q2/2024:89100 0.1M

Quarterly Profit Q3/2025:-51390 -0.1M, Q2/2025:294571 0.3M, Q1/2025:22091 0.0M, Q3/2024:215357 0.2M, Q2/2024:82610 0.1M

Quarterly Net worth Q3/2025:-3038277 -3.0M, Q2/2025:-2656263 -2.7M, Q1/2025:-5339799 -5.3M, Q3/2024:-1091416 -1.1M, Q2/2024:-4028562 -4.0M

Fund house & investment objective

Company Information BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. It develops programs relate to the treatment of disc/spine disease and metabolic disorders. The company's products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. It also operates a commercial biocosmeceutical platform. In addition, the company provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.

Organisation Biotechnology

Employees 11

Industry Biotechnology

CEO Mr. Lance Alstodt

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right